The DOI matches its Crossref record.
Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism: Melatonin Induces Prostate Neuroendocrine Differentiation
Abstract
BACKGROUND: Melatonin, the main secretory product of the pineal gland, inhibits the growth of several types of cancer cells. Melatonin limits human prostate cancer cell growth by a mechanism which involves the regulation of androgen receptor function but it is not clear whether other mechanisms may also be involved. METHODS: Time-course and dose-dependent studies were performed using androgen-dependent (LNCaP) and independent (PC3) prostate cancer cells. Cell number, cell viability, and cell cycle progression were studied. Neuroendocrine differentiation of these cells was evaluated by studying morphological and biochemical markers. Finally, molecular mechanisms including the participation of melatonin membrane receptors, intracellular cAMP levels, and the PKA signal transduction pathway were also analyzed. RESULTS: Melatonin treatment dramatically reduced the number of prostate cancer cells and stopped cell cycle progression in both LNCaP and PC3 cells. In addition, it induced cellular differentiation as indicated by obvious morphological changes and neuroendocrine biochemical parameters. The role of melatonin in cellular proliferation and differentiation of prostate cancer cells is not mediated by its membrane receptors nor related to PKA activation. CONCLUSIONS: The treatment of prostate cancer cells with pharmacological concentrations of melatonin influences not only androgen-sensitive but also androgen-insensitive epithelial prostate cancer cells. Cell differentiation promoted by melatonin is not mediated by PKA activation although it increases, in a transitory manner, intracellular cAMP levels. Melatonin markedly influences the proliferative status of prostate cancer cells. These effects should be evaluated thoroughly since melatonin levels are diminished in aged individuals when prostate cancer typically occurs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mayo, J. C., Sainz, R. M., Tan, D.-X., Hardeland, R., Leon, J., Rodriguez, C., & Reiter, R. J. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.05.002 · Cited by 332
Self-citationMelatonin as a biomarker of circadian dysregulation
Mirick, D. K., & Davis, S. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0605 · Cited by 176
Sigurdardottir, L. G., Valdimarsdottir, U. A., Fall, K., Rider, J. R., Lockley, S. W., Schernhammer, E., & Mucci, L. A. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0116 · Cited by 162
Metadata
- Authors
- Sainz, R. M., Mayo, J. C., Tan, D.-X., León, J., Manchester, L., & Reiter, R. J.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2004-09-17
- Volume
- 63
- Issue
- 1
- Pages
- 29-43
- ISSN
- 0270-4137 (ISSN-L)
- OpenAlex
- W2011663673
- Cited by
- 159
- References
- 0
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism: Melatonin Induces Prostate Neuroendocrine Differentiation. https://app.cochat.ai/papers/10.1002/pros.20155
- The paper
- Sainz, R. M., Mayo, J. C., Tan, D.-X., León, J., Manchester, L., & Reiter, R. J. (2005). Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism: Melatonin Induces Prostate Neuroendocrine Differentiation. The Prostate. https://doi.org/10.1002/pros.20155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.